+13,854.0%
NUE vs GSK
+1,698.4%
+12,155.6%
-68.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | -2.3% | +2.1% | +0.6% |
| 7D | -1.7% | -3.0% | +1.3% | -0.7% |
| 30D | -1.6% | +0.4% | -2.0% | -2.0% |
| 3M | -7.3% | -1.2% | -6.1% | -7.4% |
| 6M | +11.6% | +0.9% | +10.6% | +10.4% |
| YTD | +55.8% | +4.0% | +51.8% | +51.9% |
| 1Y | +71.5% | +7.3% | +64.2% | +65.3% |
| 3Y | +67.7% | +57.1% | +10.6% | +36.8% |
| 5Y | +148.5% | +43.0% | +105.5% | +107.0% |
| 10Y | +424.1% | +103.1% | +321.0% | +280.7% |
| All | +13,854.0% | +1,698.4% | +12,155.6% | +4,808.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling